STOCK TITAN

MEI Pharma (MEIP) Revenue by Year

MEIP NASDAQ

MEI Pharma, Inc. generated $0 in revenue in fiscal year 2025. This represents a decrease of 100.0% from the prior fiscal year. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters MEI Pharma, Inc. has filed alongside them.

FY2025 annual
Revenue $0
YoY -100.0%
Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Mar 31, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

MEIP Revenue by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY2510-KFY2410-KFY23FY22FY21FY20FY19FY18FY17FY16FY15FY14FY13FY12FY11
Revenue$0-100.0%$65.3M+33.8%$48.8M+19.9%$40.7M+17.0%$34.8M+25.4%$27.8M+464.7%$4.9M+203.0%$1.6M-93.0%$23.2MN/AN/AN/AN/AN/AN/A

MEIP Revenue by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-QQ3'25Q2'25Q1'25Q4'2410-KQ3'24Q2'24Q1'24Q4'23
Revenue$54K-73.3%$60K-78.5%N/AN/A$202Kn/m$279Kn/m$0-100.0%N/A$0-100.0%$0-100.0%$65.3M+648.0%$1.5M-87.2%

What revenue means

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it.

More MEI Pharma, Inc. financials

Frequently Asked Questions

What was MEI Pharma, Inc.'s revenue in fiscal year 2025?

MEI Pharma, Inc. generated $0 in revenue in fiscal year 2025.

How fast is MEI Pharma, Inc.'s revenue growing?

MEI Pharma, Inc. (MEIP) revenue fell by 100.0% year over year, from $65.3M to $0 in fiscal year 2025.

What was MEI Pharma, Inc.'s revenue in the most recent quarter?

MEI Pharma, Inc. (MEIP) reported $54K in revenue in Q3 2026. This represents a decrease of 73.3% from the same quarter a year earlier.

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it. This page lists what MEI Pharma, Inc. (MEIP) reported on that line in every period on record.